Reactivation of adult-onset Still’s disease after use of the COVID-19 ChAdOx1-S vaccine
Journal
BMJ Case Reports
ISSN
1757-790X
Date Issued
2022
Author(s)
Sebastián E Ibáñez Vodnizza
Luis Morales Murillo
Matías de la Rivera Vergara
Roberto Saldías Martínez
Type
Resource Types::text::journal::journal article
URL Institutional Repository
Abstract
<jats:p>A woman in her 60s with a history of adult-onset Still’s disease (AOSD) in remission for 14 years received the ChAdOx1-S vaccine as a booster to her initial vaccination schedule (two doses of CoronaVac vaccine 6 months apart). Two weeks later, she consulted for symptoms suggestive of AOSD reactivation. This was confirmed during hospitalisation, where renal and cardiac involvement were also observed. Despite using high-dose corticosteroids, troponin T and N-terminal pro hormone B-type natriuretic peptide (NT-proBNP) were persistently elevated. Tocilizumab was used, with which the patient achieved complete remission of her symptoms and normalised her laboratory tests.</jats:p>
Subjects
connective tissue disease
;
covid-19
;
adrenal cortex hormones
;
adult
;
covid-19
;
covid-19 vaccines
;
female
;
humans
;
remission induction
;
still's disease, adult-onset
;
methylprednisolone
;
tocilizumab
;
vaxzevria
;
corticosteroid
;
adult
;
adult onset still disease
;
adverse outcome
;
arthralgia
;
article
;
case report
;
clinical article
;
clinical effectiveness
;
clinical feature
;
dose response
;
drug effect
;
drug efficacy
;
dry cough
;
fatigue
;
female
;
fever
;
follow up
;
glucose 6 phosphate dehydrogenase deficiency
;
heart palpitation
;
human
;
maculopapular rash
;
middle aged
;
night sweat
;
physical examination
;
single drug dose
;
sore throat
;
treatment outcome
;
adult onset still disease
;
remission